𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

✍ Scribed by G. Goss; L. L. Siu; I. Gauthier; E. X. Chen; A. M. Oza; R. Goel; J. Maroun; J. Powers; W. Walsh; M. Maclean; D. W. Drolet; J. Rusk; L. K. Seymour

Publisher
Springer
Year
2006
Tongue
English
Weight
233 KB
Volume
58
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II study of pemetrexed disodium, a
Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma : A study of the national cancer institute of Canada clinical trials group
✍ Frances A. Shepherd; Janet Dancey; Andrew Arnold; Alan Neville; James Rusthoven; πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 90 KB πŸ‘ 3 views

## Background: Pemetrexed disodium (alimta [eli lilly and company, indianapolis, in], ly231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. phase ii trials showed single-agent response rates of 16% and 23% in untreated pati